Gregory Driessens

USPTO Granted Patents = 9 (Patent Applications = 3)

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 7)

Average Co-Inventor Count = 4.4

ph-index = 1

Forward Citations = 9(Granted Patents)

Location History:

Watermael-Boitsfort, BE (2017 - 2019)
Charleroi, BE (2021)
Gosselies, BE (2019 - 2022)
Ottignies, BE (2022)

Company Filing History:

Iteos Therapeutics Sa

where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12312401 - Anti-TIGIT antibodies (2025-05-27),

2. 11439705 - Anti-TIGIT antibodies (2022-09-13),

3. 11376255 - Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents (2022-07-05),

4. 10945994 - Combinations comprising a pyrrolidine-2,5-dione IDO1 inhibitor and an anti-body (2021-03-16),

5. 10398679 - Treatment method utilizing pyrrolidine-2, 5-dione derivatives as IDO1 inhibitors (2019-09-03),

6. 10329349 - Anti-TIGIT antibodies (2019-06-25),

7. 9949951 - Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors (2018-04-24),

8. 9758505 - 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use (2017-09-12),

9. 9603836 - Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors (2017-03-28),

Title: Gregory Driessens: Innovator in Anti-TIGIT Antibodies

Introduction

Gregory Driessens is a notable inventor based in Watermael-Boitsfort, Belgium. He has made significant contributions to the field of biotechnology, particularly in the development of anti-TIGIT antibodies. With a total of nine patents to his name, Driessens has established himself as a key figure in innovative therapeutic solutions.

Latest Patents

Driessens' latest patents focus on anti-TIGIT antibodies and their antigen binding fragments that inhibit TIGIT-mediated signaling. These patents detail methods for promoting T cell activity and treating cancer using these antibodies. The full patent texts provide comprehensive information on the combinations of these antibodies with additional therapeutic agents, as well as methods applicable to human subjects.

Career Highlights

Throughout his career, Gregory Driessens has worked with prominent companies in the biotechnology sector, including Iteos Therapeutics and Iteos Belgium SA. His work has been instrumental in advancing therapeutic strategies that leverage the immune system to combat cancer.

Collaborations

Driessens has collaborated with esteemed colleagues such as Stefano Crosignani and Sandra Cauwenberghs. These partnerships have contributed to the development of innovative solutions in the field of immunotherapy.

Conclusion

Gregory Driessens is a pioneering inventor whose work on anti-TIGIT antibodies has the potential to transform cancer treatment. His contributions to biotechnology continue to inspire advancements in therapeutic approaches.

This text is generated by artificial intelligence and may not be accurate.